Grandfield & Dodd LLC increased its position in Sanofi (NYSE:SNY) by 3.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 246,489 shares of the company’s stock after buying an additional 8,921 shares during the quarter. Grandfield & Dodd LLC’s holdings in Sanofi were worth $12,273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA lifted its position in Sanofi by 8.3% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,374 shares of the company’s stock worth $765,000 after buying an additional 1,183 shares during the last quarter. HL Financial Services LLC lifted its position in Sanofi by 22.8% in the 3rd quarter. HL Financial Services LLC now owns 15,044 shares of the company’s stock worth $749,000 after buying an additional 2,797 shares during the last quarter. River Road Asset Management LLC bought a new stake in Sanofi in the 3rd quarter worth approximately $208,000. Boston Partners lifted its position in Sanofi by 6.2% in the 3rd quarter. Boston Partners now owns 8,664,983 shares of the company’s stock worth $431,429,000 after buying an additional 503,799 shares during the last quarter. Finally, Alethea Capital Management LLC bought a new stake in Sanofi in the 3rd quarter worth approximately $794,000. Institutional investors own 9.36% of the company’s stock.
In other Sanofi news, major shareholder Sanofi bought 105,820 shares of Sanofi stock in a transaction dated Thursday, August 24th. The shares were purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by insiders.
Several brokerages have weighed in on SNY. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Argus reiterated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $53.50.
“Grandfield & Dodd LLC Purchases 8,921 Shares of Sanofi (SNY)” was originally reported by GBand is the property of of DT GB gearsofbiz and and international and trademark . of 2017/11/10/grandfield-dodd-llc-purchases-8921-shares-of-sanofi-sny
Sanofi (NYSE:SNY) traded down $0.46 on Friday, hitting $44.96. The stock had a trading volume of 712,234 shares, compared to its average volume of 1,440,000. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. Sanofi has a 52-week low of $38.45 and a 52-week high of $50.65. The stock has a market capitalization of $113,110.00, a PE ratio of 14.47, a PEG ratio of 2.53 and a beta of 0.88.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.